R
Raman Mahadevan Iyer
Researcher at Hoffmann-La Roche
Publications - 11
Citations - 2655
Raman Mahadevan Iyer is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Solubility & Vemurafenib. The author has an hindex of 10, co-authored 11 publications receiving 2445 citations.
Papers
More filters
Journal ArticleDOI
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma
Gideon Bollag,Peter Hirth,James Tsai,Jiazhong Zhang,Prabha N. Ibrahim,Hanna Cho,Wayne Spevak,Chao Zhang,Ying Zhang,Gaston Habets,Elizabeth A. Burton,Bernice Wong,Garson Tsang,Brian L. West,Ben Powell,Rafe Shellooe,Adhirai Marimuthu,Hoa Nguyen,Kam Y. J. Zhang,Dean R. Artis,Joseph Schlessinger,Fei Su,Brian Higgins,Raman Mahadevan Iyer,Kurt D'Andrea,Astrid Koehler,Michael Stumm,Paul S. Lin,Richard J. Lee,Joseph F. Grippo,Igor Puzanov,Kevin B. Kim,Antoni Ribas,Grant A. McArthur,Jeffrey A. Sosman,Paul B. Chapman,Keith T. Flaherty,Xiaowei Xu,Katherine L. Nathanson,K. B. Nolop +39 more
TL;DR: The structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity, and a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily are described, demonstrating that BRAF-mutant melanomas are highly dependent on B- RAF kinases activity.
Journal ArticleDOI
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
Hong Yang,Brian Higgins,Kenneth Kolinsky,Packman Kathryn E,Zenaida Go,Raman Mahadevan Iyer,Stanley P. Kolis,Sylvia Zhao,Richard T. Lee,Joseph F. Grippo,Kathleen Schostack,Mary Simcox,David C. Heimbrook,Gideon Bollag,Fei Su +14 more
TL;DR: In several tumor xenograft models of BRAF(V600E)-expressing melanoma, it was found that RG7204 treatment caused partial or complete tumor regressions and improved animal survival, in a dose-dependent manner, and no toxicity observed in any dose group in any of the in vivo models tested.
Journal ArticleDOI
Characterization of physico‐mechanical properties of indomethacin and polymers to assess their suitability for hot‐melt extrusion processs as a means to manufacture solid dispersion/solution
Rina J. Chokshi,Rina J. Chokshi,Harpreet K. Sandhu,Raman Mahadevan Iyer,Navnit Hargovindas Shah,A. Waseem Malick,Hossein Zia +6 more
TL;DR: The understanding of thermal and rheological properties of the various drug/polymer mixtures help established the processing conditions for hotmelt extrusion (such as extrusion temperatures and motor load) as well as provided insight into the properties ofThe final extrudates.
Journal ArticleDOI
Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process.
Navnit Hargovindas Shah,Raman Mahadevan Iyer,Hans-Juergen Mair,Duk Soon Choi,Hung Tian,Ralph Diodone,Karsten Fähnrich,Anni Pabst-Ravot,K. Tang,Emmanuel Scheubel,Joseph F. Grippo,Sebastian Moreira,Zenaida Go,James Mouskountakis,Theresa Louie,Prabha N. Ibrahim,Harpreet K. Sandhu,Linda Rubia,Hitesh Chokshi,Dharmendra Singhal,Waseem Malick +20 more
TL;DR: In a relative human bioavailability study, vemurafenib MBP provided a four- to fivefold increase in exposure compared with crystalline drug, and improving solubility with an amorphous-solid dispersion is a viable strategy for the development of practically insoluble compounds.
Journal ArticleDOI
Stability assessment of hypromellose acetate succinate (HPMCAS) NF for application in hot melt extrusion (HME).
Ashish L. Sarode,Sakae Obara,Fumie Tanno,Harpreet K. Sandhu,Raman Mahadevan Iyer,Navnit Hargovindas Shah +5 more
TL;DR: The HME processing conditions for solid dispersions of HPMCAS should be based on the acceptance levels of free acid for the drug and the drug product.